Novo Nordisk: 'very encouraging' data in hemophilia A
According to the Danish pharmaceutical company, no bleeding was observed in 85.7% of people treated with its experimental product Mim8 once a week, and in 95% of those treated with Mim8 once a month.
Novo Nordisk aims to submit Mim8 for first regulatory approval towards the end of 2024. Data from the ongoing phase 3 FRONTIER program will be unveiled at upcoming congresses and in publications in 2024 and 2025.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction